KAS
XENE icon

Kestra Advisory Services’s Xenon Pharmaceuticals XENE Stock Holding History

Kestra Advisory Services’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-740
Closed -$33.2K – 4417
2025
Q4 		$33.2K Buy
+740
New +$31.1K ﹤0.01% 4228

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Kestra Advisory Services's XENE Position: Q1 2026 in Review

Kestra Advisory Services sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 740 shares — an estimated $33.2K sold.

Kestra Advisory Services first reported a position in XENE in Q4 2025 and held it in 1 quarter. The position peaked at $33.2K in Q4 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Kestra Advisory Services reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 740 Xenon Pharmaceuticals shares in Q1 2026, an estimated $33.2K.
  • Kestra Advisory Services first reported a position in Xenon Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Kestra Advisory Services's Xenon Pharmaceuticals position peaked at $33.2K in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.